Abstracts on Allos Therapeutics' RSR13 to Be Presented at American Society of Clinical Oncology Annual Meeting
28 Mai 2004 - 3:00PM
PR Newswire (US)
Abstracts on Allos Therapeutics' RSR13 to Be Presented at American
Society of Clinical Oncology Annual Meeting Data Also to Be
Presented on PDX WESTMINSTER, Colo., May 28 /PRNewswire-FirstCall/
-- Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced that data
from poster sessions and abstracts on RSR13 (efaproxiral), the
company's investigational radiation sensitizer and PDX
(pralatrexate), an injectable small molecule chemotherapeutic agent
will be presented at the Annual Meeting of the American Society of
Clinical Oncology (ASCO) to be held from June 5th to June 8th in
New Orleans, Louisiana. Allos Therapeutics, Inc. will host booth
#927 at the meeting. The presentations are scheduled as follows:
RSR13 (efaproxiral) * Standard Whole Brain Radiation Therapy (WBRT)
with supplemental oxygen (O2) with or without RSR13 (efaproxiral)
in patients with brain metastases originating from NSCLC: Results
of a subgroup analysis. Poster Presentation. Saturday June 5, 2004,
8:00 a.m. - 12:00 p.m. (Abstract #7115; Poster U3) Presenter:
Abdenour Nabid, MD, Centre Hospitalier Universitarie de Sherbrooke,
Sherbrooke, PQ, Canada * Standard Whole Brain Radiation Therapy
(WBRT) with supplemental oxygen (O2), with or without RSR13
(efaproxiral) in patients with brain metastases: Results of the
randomized REACH (RT-009) study. Poster Presentation. Saturday,
June 5, 2004, 1:00 - 5:00 p.m. (Abstract #1534; Poster 25)
Presenter: John H. Suh, M.D., Clinical Director, Radiation
Oncology, Brain Tumor Institute at the Cleveland Clinic Foundation
* Evaluation of safety and tolerance of escalating doses of RSR13
(efaproxiral) administered with a fixed dose of BCNU every six
weeks in patients with recurrent malignant glioma: Results of the
phase I NABTT 9806 clinical trial. Poster Presentation. Saturday,
June 5, 2004, 1:00 - 5:00 p.m. (Abstract #1533; Poster 24)
Presenter: Pamela Z. New, DO, Assistant Professor, Department of
Neurosurgery, Baylor College of Medicine, Houston, Texas *
Pharmacokinetics (PK) of RSR13 (efaproxiral) predict survival in
patients with brain metastases randomized to receive whole brain
radiation therapy (WBRT) with or without RSR13 (REACH RT-009).
Poster Presentation. Sunday, June 6, 2004, 1:00 p.m. - 5:00 p.m.
(Abstract #1561; Poster C5) Presenter: Edward G. Shaw, MD,
Department of Radiation Oncology, Wake Forest University School of
Medicine, Winston-Salem, North Carolina * Safety profile of
efaproxiral (RSR13), a novel radiation sensitizer, in patients
undergoing radiation therapy. (Abstract No: 3090 -- no presentation
or poster session) Author: Baldassare Stea, M.D., Ph.D. Head of the
Department of Radiation Oncology, Arizona Health Sciences Center in
Tuscon, AZ, et al. PDX (pralatrexate) * A novel antifolate
10-propargyl-10-deazaaminopterin (PDX) displays synergistic effects
with gemcitabine in non-Hodgkin's lymphoma models in vitro and in
vivo. Poster Presentation. Sunday, June 6, 2004, 8:00 a.m. - 12:00
p.m. (Abstract No: 6596; Poster K7) Presenter: Radovan Vrhovac, MD,
PhD., Memorial Sloan Kettering Hospital All abstracts may be
accessed online at http://www.asco.org/ at the conclusion of the
meeting. The poster presentations will not be web cast. About ASCO
The American Society of Clinical Oncology (ASCO) is the world's
leading professional organization representing physicians who treat
people with cancer. ASCO's members set the standard for patient
care worldwide and lead the fight for more effective cancer
treatments, increased funding for clinical and translational
research, and, ultimately, cures for the many different cancers
that strike millions of people around the world every year. About
Allos Therapeutics, Inc. Allos Therapeutics, Inc. is a
biopharmaceutical company focused on developing and commercializing
innovative drugs for improving cancer treatments. The company's
lead clinical candidate, RSR13 (efaproxiral), is a synthetic small
molecule that has the potential to sensitize hypoxic (oxygen
deprived) tumor tissues and enhance the efficacy of standard
radiation therapy. Allos recently launched a multi-center Phase 3
randomized open label trial of RSR13 (efaproxiral) as an adjunct to
whole brain radiation therapy for the treatment of brain metastases
from breast cancer. The trial, called ENRICH (ENhancing Whole Brain
Radiation Therapy In Patients with Breast Cancer and Hypoxic Brain
Metastases), will seek to enroll approximately 360 patients at up
to 50 cancer centers across North America. In addition, Allos is
developing PDX, an injectable small molecule chemotherapeutic agent
that has an enhanced potency and toxicity profile relative to
methotrexate and other dihydrofolate reductase, or DHFR,
inhibitors. For more information, please visit the company's web
site at: http://www.allos.com/. DATASOURCE: Allos Therapeutics,
Inc. CONTACT: Fern Lazar of Lazar Partners Limited,
+1-212-867-1762, , for Allos Therapeutics, Inc. Web site:
http://www.asco.org/ Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024